Investigating the Safety of JZP441 for Sleep-deprived Healthy Participants
Unknown Phase 1 NCT05651152
Study Description
This study aims to analyze JZP441's safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in sleep-deprived healthy participants. The study is Phase 1, double-blind and randomized, placebo-controlled. The participants (up to 12 per cohort) will receive ascending nighttime doses initially. They will remain awake during the day and will be dosed at night for safety, tolerability, PK, and PD assessments.
Study Details
- Registry ID:
- NCT05651152
- Conditions:
- Healthy Participants
- Phase:
- Phase 1
- Target Enrollment:
- 105 participants
- Start Date:
- Age Range:
- 18–50 years
- Healthy Volunteers:
- No
Study Locations (2 sites)
-
Clinical Site 1
Eatontown, New Jersey, United States -
Clinical Site 2
New York, New York, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.